How Scientists Engineer Insulin, GLP-1, and Other Diabetes Peptide Drugs for Better Performance | Research

The takeaway

Molecular engineering strategies including amino acid substitutions, peptide stapling, PEGylation, and glucose-responsive systems are transforming diabetes peptide therapeutics toward oral delivery and automated glucose control.

Full engineering toolkit
Covers amino acid modifications, stapling, PEGylation, oral/inhaled delivery, multi-receptor agonists, and glucose-responsive systems

What the researchers found

Core molecular engineering strategies—sequence modifications, formulation-based depot formation, and vascular binding—enable the diverse pharmacokinetic profiles needed across insulin, glucagon, amylin, and GLP-1 therapeutics for diabetes.

Why it matters

Diabetes peptide drugs are used by hundreds of millions of people. Understanding the engineering principles behind them informs the development of next-generation therapeutics with better efficacy, convenience, and safety.

How the study worked

Comprehensive narrative review of molecular design principles across all major classes of diabetes peptide therapeutics, from structural modifications to delivery systems and glucose-responsive technologies.

What this study cannot tell us

Review covers broad territory without depth on individual compounds. Some technologies discussed are still early-stage. Not all engineering strategies translate from concept to clinical success.

How to read the evidence

Comprehensive review integrating established clinical evidence with emerging technologies. Authoritative overview of the field.

When this study was published

Published in 2025, capturing the current state of diabetes peptide engineering.

The bigger picture

The diabetes field serves as a masterclass in peptide drug engineering. The strategies developed here—from half-life extension to oral delivery to glucose-responsive systems—provide a framework applicable to peptide therapeutics across all diseases.

Questions still open

When will glucose-responsive insulin systems become clinically available?
Can multi-receptor agonist peptides be designed to treat conditions beyond diabetes?
What engineering approaches will enable reliable oral delivery of larger peptides?

Common questions

Why do diabetes peptide drugs need engineering?

Natural hormones like insulin and GLP-1 are fragile—they break down quickly in the body and can't be taken orally. Engineering modifications make them more stable, longer-lasting, and deliverable through convenient routes.

What is a glucose-responsive insulin system?

It's a next-generation technology where insulin is released automatically when blood sugar rises and stops when it falls—mimicking what a healthy pancreas does. Several molecular and materials-based approaches are being developed to achieve this.

Read the original research

Molecular engineering of designer diabetes therapeutics.

Journal of controlled release : official journal of the Controlled Release Society, 392, 114705

View on PubMed ↗Publisher’s paper ↗

Citation

DeWolf, Emily L; Webber, Bernice; Webber, Matthew J. (2026). Molecular engineering of designer diabetes therapeutics.. Journal of controlled release : official journal of the Controlled Release Society, 392, 114705. https://doi.org/10.1016/j.jconrel.2026.114705